Health
Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar ® Gel) for Persistently Active Systemic Lupus Erythematosus – DocWire News
Introduction: We assessed patient-reported outcomes from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin
Introduction: We assessed patient-reported outcomes from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection (RCI; Acthar® Gel) in patients with persistently active systemic lupus erythematosus (SLE) despite treatment with moderate-dose glucocorticoids.
Methods: The trial enrolled adults with active SLE and moderate-to-severe rash and/or arthritis despite use of stable glucocorticoids (7.5 mg/day to 30 mg/day prednisone equivalent), antimalarials,…
-
Noosa News24 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation
-
General23 hours agoPort’s lease a ‘mistake’ as major parties flag takeover
-
Business22 hours agoThese ASX 200 shares could rise 50% to 60%
-
General21 hours agoAustralia’s Myanmar community mourns earthquake losses